Phaseline

Companies › Aurion Biotech

Aurion Biotech: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Ophthalmology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cryopreserved AURN001
Corneal endothelial cell therapy with Rho kinase inhibitor
ROCK1, ROCK2Phase 3Corneal EdemaJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06630169Cryopreserved AURN001Phase 2Corneal EdemaOphthalmologyOct 2025
NCT07368959Cryopreserved AURN001Phase 3Corneal EdemaOphthalmologyJun 2027

Targets

ROCK1 (1) ROCK2 (1)

Companies with the same targets

Woolsey Pharmaceuticals Sanofi Chia Tai Tianqing Pharmaceutical Group

Companies built like this

Cloudbreak Therapeutics Omikron Italia S.r.l. Viridian Therapeutics Smilebiotek Zhuhai Beletalent (Zhuhai) Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.